2024 is the "first year" of commercialization of large artificial intelligence models, and various large model technologies are gradually implementing specific scenarios for commercialization exploration. On November 14, the National Health Commission and three other ministries and commissions jointly issued the "Reference Guidelines for Artificial Intelligence Application Scenarios in the Health and Health Industry" (hereinafter referred to as the "Guidelines"), which also pointed out the direction for the innovative application of "Artificial Intelligence +" in the medical field.
It is reported that for the application of digital technology and AI technology in the medical field, some companies have made plans in this direction as early as three years ago. For some specific diagnosis and treatment scenarios mentioned in the "Guidelines", such as "intelligent assisted diagnosis of medical imaging", the company has also realized it. This is Meinian Health, a leading company in artificial intelligence in the medical field.
"With the attention of the national and local governments, relevant favorable policies have been continuously introduced, promoting the deep integration and healthy development of artificial intelligence in multiple industries. Based on the annual customer service scale of nearly 30 million, Meinian has hundreds of millions of professional health services With the advantages of data accumulation and application scenarios in more than 600 branches, Meinian will seize the opportunities of the times and ride on the momentum. In the next three years, Meinian will fully implement the 'ALL IN AI' strategy, aiming to become a leading company in the field of digital intelligent health management. , becoming the leader in the medical + AI industry," said Yu Rong, chairman of Meinian Health Group.
"All in digital" realizes multiple scenario applications such as intelligent auxiliary diagnosis of medical imaging
Specifically, the "Guidelines" focus on the four major areas of combining "artificial intelligence﹢" with medical service management, grassroots public health services, health industry development, and medical teaching and research, and clarify the requirements of 84 subdivided areas such as intelligent assisted diagnosis of medical imaging. Basic concepts and application scenarios.
In the above scenario, Meinian Health has already implemented it in multiple directions. For example, the first scenario listed in the "Guidelines" is "intelligent assisted diagnosis of medical imaging" in "artificial intelligence +" medical service management. The basic concept is: intelligent analysis, rapid reading, and report generation of medical imaging data. Achieve efficient and accurate medical image-assisted diagnosis.
In this regard, Meinian Health has introduced advanced physical examination equipment at home and abroad, including DR, low-dose spiral CT, MRI, ultrasound, capsule gastroscopy, fundus AI and other imaging examination equipment. Combined with AI technology, tiny lesions can be accurately and quickly discovered from massive images, greatly improving the accuracy and quality of image-assisted diagnosis and enabling accurate early screening of key diseases. With the help of AI image-assisted screening function, Meinian Health further improves screening efficiency, relieves doctors' pressure in reading pictures, and realizes "AI-assisted picture reading".
Meinian Health has also implemented the "electronic cloud film" function to meet patients' medical needs and achieve interconnection and mutual recognition of imaging data. "Cloud Film" uses the Internet and cloud storage technology to provide patients with a variety of original DICOM imaging data. Patients can use various smart terminals, such as mobile phones, computers, etc., to easily access imaging data and imaging reports anytime, anywhere, with safety features , fast, convenient, unique, private and other conveniences.
In fact, Meinian Health has widely used artificial intelligence-assisted diagnosis technology in various physical examination items and innovative products. For example, AI Pulmonary Nodule - AI technology-assisted image e+ retrospective pulmonary nodule in-depth analysis report. This product uses AI technology based on thin-section CT to assist in the discovery and judgment of pulmonary nodules and their attribute values; three-dimensional reconstruction technology : Construct a 3D whole-lung map to clearly mark the bronchus where the pulmonary nodule is located, as well as the pulmonary artery and vein passage, which is helpful for accurately locating and judging the benign and malignant degree of the pulmonary nodule; Online pulmonary nodule service: from a tertiary hospital that has been engaged in lung cancer diagnosis and treatment for a long time The radiologists use AI and three-dimensional reconstruction technology to assist in reading the pictures, form a detailed report, and list the nature of each pulmonary nodule and the subsequent follow-up plan.
In addition, in terms of intelligent outpatient triage, intelligent medical record auxiliary generation, traditional Chinese medicine clinical intelligent auxiliary diagnosis and treatment, intelligent medical quality management, intelligent health management, intelligent public health group data analysis, etc., Meinian Health has also achieved all relevant scenarios. application.
"Continuously launch AI products" has launched specialized new products such as Feijiening and Naoruijia.
How does Meinian Health do it? Yu Rong said that three years ago, Meinian Health proposed the "All in Digital" strategy, and in 2024, the company upgraded it to "All in AI." At present, Meinian Health's AI layout is mainly reflected in the continuous launch of specialized new products, the use of AI to empower marketing and refined operations, the reshaping of the physical examination chain through AI empowerment, and the release of China's first private AI health management based on large-scale model technology. Teacher - four aspects of health and beauty.
Among them, in terms of the first-level layout of “continuously launching AI products”, Meinian Health has currently launched Feijiening, Naoruijia, Coronary Artery Calcification Points, etc. to the public. In Meinian Health, the company calls the products it launches using AI technology special new products.
As the first comprehensive management service project for pulmonary nodules in the industry, Feijie Ning is one of the most representative products in the implementation of Meinian Health’s “All in AI” strategy.
In 2017, Meinian Health began AI-assisted diagnosis of pulmonary nodules. After a large amount of practice accumulation, in 2022, the company launched the comprehensive lung health service package Fei Jie Ning. Fei Jie Ning includes comprehensive seven-type lung cancer antibody blood tests, imaging E+ retrospective pulmonary nodule in-depth analysis reports, lung health service packages, and lung malignant tumor insurance.
In layman's terms, if a subject chooses this product, once small pulmonary nodules are discovered during the examination, they can receive services that go beyond detection, such as report interpretation, lung cancer risk assessment, and even lung cancer diagnosis and treatment services. As a result, through the product Feijiening, we can realize full-link services of early lung cancer screening, early diagnosis, follow-up management, and lung cancer diagnosis and treatment intervention.
After Fei Jie Ning, Meinian Health launched “Nao Ruijia” in 2022. This is another typical product in the implementation of Meinian Health’s “All in AI” strategy. It is also the first brain health screening product on the market for stroke and Alzheimer’s (AD).
In the product Nauruijia, Meinian Health can not only provide MRI, a scarce service in the market, but also create a brain standard library of more than 100,000 healthy people based on an average of tens of millions of healthy people per year. After comparing MRI and standard libraries, Nauruijia can also use AI image technology to predict risks and assess the subject's brain health risk status.
Up to now, Feijiening has served more than 100,000 people, with products covering more than 130 cities; Naoruijia has screened more than 200,000 people, with products covering more than 220 cities, with a medium- and high-risk abnormality detection rate of 14%.
This year, at the company’s 20th anniversary celebration, Meinian Health officially launched China’s first health management AI robot, Healthy Xiaomei. It is also an important achievement of Meinian Health’s comprehensive implementation of the “All in AI” strategy, and represents a key step for Meinian Health in the field of digital intelligent health management.
Health Xiaomei is the first domestic AI intelligent personal health manager released based on large-scale model technology. It brings a new health management model to consumers and is a good start for the personalized and digital development of the physical examination industry. Health Xiaomei has done a good job in responding to the three major trends of real-time consultation on personal health issues, comprehensive understanding of health data trends, and personalized health management plans.
At the same time, Meinian Health Group also integrated high-quality resources to launch "AI intelligent blood sugar management innovative products". This product adopts an innovative "three-teacher co-management" (physician, nutritionist, and exercise instructor) model to provide users with comprehensive and personalized blood sugar management services. Its service model relies on a blood sugar management system supported by 230 million pieces of data to ensure The scientific nature and accuracy of the service.
It is worth mentioning that this product’s AI intelligent sugar control assistant not only uses advanced system software intelligence and AI technology to provide dynamic blood sugar monitoring, but also combines the scientific deployment of functional nutrients to provide medication guidance, dietary adjustment, exercise advice, etc. Each user customizes a personalized blood sugar management plan of "one person, one strategy".
In addition, in terms of digital marketing, Meinian Health is building a sales team powered by AI. Yu Rong mentioned that in the second quarter of 2024, Meinian Health's AI intelligent sales assistant "Meinian Xiaoxing" based on large-scale model technology has been piloted in Hangzhou. During the one-month test period of the AI sales agency operation project, "Meinian Xiaoxing" was able to complete sales transactions with a conversion rate of 8.02% through its Qiwei account, and the average customer price increased by 1,492.27 yuan.
The unit price per customer has increased to double digits for two consecutive years. “All in AI” has brought about performance transformation.
In addition to the scenarios that have been realized, the "All in AI" strategy is also pushing Meinian Health into the leading enterprise of medical artificial intelligence in China. It is understood that Meinian Health is currently stepping up its efforts to lay out future planable scenarios, including intelligent assisted quality control of medical imaging data, intelligent medical insurance accounting, intelligent hospital economic management decision support, intelligent occupational health risk assessment, intelligent health management of the elderly, etc., among which Many directions coincide with the Guidelines.
Yu Rong gave an example, in the "Intelligent Hospital Economic Management Decision Support" scenario proposed in the "Guidelines", in the future, for the intelligent economic management decision support applications of more than 600 physical examination branches of Meinian Health, we can establish an intelligent economic management system and integrate artificial intelligence Intelligent technology analyzes each store's financial, operational and resource data. The system can automatically monitor key indicators such as revenue, costs, equipment utilization, and personnel scheduling, and predict future operating trends through AI algorithms to help management make more scientific and accurate decisions. This system can also realize cross-store data sharing and comparison, optimize resource allocation, and improve overall operational efficiency and cost-effectiveness.
At the same time, the intelligent decision support platform can provide real-time financial health monitoring, risk warning and intelligent budget optimization for each store, helping stores to detect financial risks in a timely manner and adjust strategies to improve the efficiency of fund use. Optimizing customer demand analysis, charge management and service processes through AI technology can improve customer satisfaction and increase revenue. On the whole, the intelligent economic management system will promote the operation and financial management of Meinian Health's physical examination stores to become more efficient, accurate and intelligent.
In response to the "intelligent-assisted quality control of medical imaging data" scenario proposed in the "Guidelines", Meinian Health is further strengthening the intelligent quality control of medical imaging data, especially in the field of ultrasound. Currently, it is using AI algorithm models to combine massive ultrasound images Multi-modal fusion learning of data, pathology, genes, etc. gradually realizes intelligent image recognition, image and text error correction, and intelligent quality control covering all ultrasound organs, empowering the ultrasound information upgrade management of each Meinian branch, and realizing the application of ultrasound AI. Landed.
Yu Rong said that the AI layout has brought real performance transformation to Meinian Health. In the past two or three years, based on the application of AI in corporate operations and the launch of innovative, specialized and special new products, the company's operations have been significantly boosted, and the unit price per customer has continued and steadily increased. Especially in 2022 and 2023, the group's unit price per customer has increased significantly. The improvement in one year has reached double digits.
In 2023, Meinian Health will generate approximately 9% of its revenue through innovative products. In 2023, as a listed company, Meinian Health achieved revenue of over 10 billion yuan for the first time - the company achieved revenue of 10.9 billion yuan during the period, a year-on-year increase of 26%; the number of inspections increased by 13%, the unit price per customer increased by 11%, and the volume achieved Prices rose simultaneously; net profit during the same period also exceeded 500 million yuan.
In the first three quarters of this year, the AI specialized new product series, including products such as Feijie Ning, Naoruijia, coronary artery calcium score, AI-MDT multidisciplinary expert intelligent health system, and digital cloud film, have achieved sustainable growth. The rapid growth also fully demonstrates Meinian’s innovation capabilities and market competitiveness in the field of artificial intelligence.
Yu Rong said that based on current achievements, Meinian Health’s vision for the AI direction in the future mainly includes five aspects: first, research and development of new technologies, continue to increase investment in AI technology research and development, and continue to launch specialized and new AI Innovative products; second, continue to build new platforms and deepen multi-party cooperation to meet the increasingly diverse health needs of customers, including management of the entire physical examination process, as well as in-depth cooperation with partners such as hospitals, insurance companies, and health management centers; third Third, continue to implement refined operations and continue to empower with "AI + medical care"; fourth, establish new standards, participate in the standard formulation of AI technology, and lead the standardized development of the industry; fifth, build a new ecology of health management AI, promote products and Innovation in service models.
"This year marks the 20th anniversary of the establishment of Meinian Health. At this point in time, the company has very clearly seen the challenges of the entire industry, and is also keenly aware of the opportunities of the times brought by the iterative wave of AI and large model technology. As the largest health care company in China With data access, Meinian Health has more confidence, more opportunities, and more ability than ever before to upgrade the company from a leading enterprise in the field of prevention to a comprehensive, full life cycle digital health management leader," said Yu Rong. .